Bioporto CEO holds Covid-19 test at arm's length: "Could be everything or nothing"

Bioporto CEO Peter Mørch Eriksen won't realize the diagnostics firm's hope of a Covid-19 home test – until the sensitivity of the product sets itself significantly apart from other tests in the market.

Bioporto CEO Peter Mørch Eriksen. | Photo: Gregers Tycho/ERH

The Covid-19 pandemic and the world-spanning battle against it have delayed the California studies in which Danish diagnostics company Bioporto has been testing a quick saliva test for coronavirus, which people would ideally be able to bring home with them.

The firm's CEO Peter Mørch Eriksen still patiently awaits the results from the trials, but he won't factor in any potential revenue from the test in Bioporto's predicted fiscal year until he sees the results.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs